Literature DB >> 24936850

The importance of hapten-protein complex formation in the development of drug allergy.

Lee Faulkner1, Xiaoli Meng, B Kevin Park, Dean J Naisbitt.   

Abstract

PURPOSE OF REVIEW: Drug allergy is an adverse drug reaction that is immune-mediated. Immune activation can occur when drugs or haptens bind covalently to proteins and then act as antigens. The purpose of this review is to summarize the recent data on the formation of hapten-protein complexes and to assess the importance of these complexes in the generation of drug allergy. RECENT
FINDINGS: The formation of hapten-protein complexes by drugs and their reactive metabolites has largely been investigated using model proteins such as human serum albumin. Precise identification of the structure of the hapten and the resulting modified residue(s) in the protein has been undertaken for a small number of drugs, such as p-phenylenediamine, nevirapine, carbamazepine, β-lactams and abacavir. Some progress has also been made in identifying hapten-protein complexes in the serum of patients with allergy.
SUMMARY: Drug-specific T cells have been isolated from different patients with allergy. Formation of hapten-protein complexes, their processing and antigen presentation have been implicated in the development of drug allergy to p-phenylenediamine, sulfonamides and β-lactams. However, evidence also supports the pi mechanism of immune activation wherein drugs interact directly with immune receptors. Thus, multiple mechanisms of immune activation may occur for the same drug.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24936850     DOI: 10.1097/ACI.0000000000000078

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  8 in total

Review 1.  New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.

Authors:  Aaron W Michels; David A Ostrov
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

2.  Biomonitoring Human Albumin Adducts: The Past, the Present, and the Future.

Authors:  Gabriele Sabbioni; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2016-12-18       Impact factor: 3.739

3.  Structural Elements Recognized by Abacavir-Induced T Cells.

Authors:  Daniel Yerly; Yuri Andreiw Pompeu; Ryan J Schutte; Klara K Eriksson; Anette Strhyn; Austin W Bracey; Soren Buus; David A Ostrov
Journal:  Int J Mol Sci       Date:  2017-07-07       Impact factor: 5.923

4.  The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity.

Authors:  Gwendolin S Simper; Lareen S Gräser; Alexander A Celik; Joachim Kuhn; Heike Kunze-Schumacher; Gia-Gia T Hò; Rainer Blasczyk; Andreas Pich; Christina Bade-Doeding
Journal:  Pharmaceutics       Date:  2019-10-15       Impact factor: 6.321

5.  Amoxicillin Inactivation by Thiol-Catalyzed Cyclization Reduces Protein Haptenation and Antibacterial Potency.

Authors:  María A Pajares; Tahl Zimmerman; Francisco J Sánchez-Gómez; Adriana Ariza; María J Torres; Miguel Blanca; F Javier Cañada; María I Montañez; Dolores Pérez-Sala
Journal:  Front Pharmacol       Date:  2020-03-04       Impact factor: 5.810

6.  Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides.

Authors:  Montserrat Puig; Suryatheja Ananthula; Ramesh Venna; Swamy Kumar Polumuri; Elliot Mattson; Lacey M Walker; Marco Cardone; Mayumi Takahashi; Shan Su; Lisa F Boyd; Kannan Natarajan; Galina Abdoulaeva; Wells W Wu; Gregory Roderiquez; William H Hildebrand; Serge L Beaucage; Zhihua Li; David H Margulies; Michael A Norcross
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

Review 7.  Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.

Authors:  Warner W Carr; Neal Jain; J Wesley Sublett
Journal:  Adv Ther       Date:  2021-09-13       Impact factor: 3.845

8.  Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.

Authors:  Gwendolin S Simper; Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Joachim Kuhn; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.